From USD 2.69 billion in 2022 to USD 3.92 billion by 2031, the worldwide biobanking industry is expected to rise at a CAGR of 8.9%. Thanks in great part to superior healthcare infrastructure and large R&D spending, North America rules the market.
Rising demand for tailored medication, developments in biomedical research, and growing frequency of chronic diseases are driving strong expansion in the biobanking industry. Supporting genomics research, drug discovery, and storage and management of biological samples, biobanks are absolutely vital. The COVID-19 epidemic has underlined even more the value of biobanks for the study of infectious diseases and the formulation of vaccines.
Market Trend: Adoption of robotics and automation in biobanking activities to improve sample purity and efficiency
To expedite sample handling, storage, and retrieval, the biobanking sector is seeing a major turn toward robotics and automation. The demand to precisely manage vast amounts of biological samples and reduce human error drives this trend. Among its various benefits are better sample tracking, lower contamination concerns, and more storage capacity provided by automated biobanking systems. Faster processing times, higher throughput, and improved temperature control are made possible by robotics' inclusion into biobanking processes. Automated systems can allow 24-hour operations, therefore lowering labor expenses and raising general efficiency. Biobanks are funding innovative automation technologies more and more as the demand for premium biological samples keeps rising to satisfy changing needs of researchers and pharmaceutical corporations.
Market Driver: Growing emphasis on biomarker discovery and precision medicine drives demand for premium biospecimens.
One main engine driving the expansion of the biobanking industry is the growing focus on biomarker discovery and precision medicine. Based on their genetic, environmental, and lifestyle choices, precision medicine seeks to customize medical treatments to each patient. This method calls for a wide spectrum of premium biospecimens in order to find and validate biomarkers connected to certain diseases or treatment reactions. Collecting, processing, and keeping these priceless samples—including blood, tissues, and genetic material—also depend critically on biobanks. Well-annotated biospecimens let researchers create focused treatments, do extensive genetic studies, and find fresh diagnostic markers. The demand for biobanking services and infrastructure keeps growing as pharmaceutical companies and research facilities step up their efforts in precision medicine, therefore promoting market development and innovation in sample management technology.
Market Restraint : Ethical and legal issues related to biospecimen procurement and application
The complicated terrain of ethical and legal questions surrounding biospecimen collecting, storage, and use represents one of the main constraints confronting the biobanking industry. For biobanks, issues about patient privacy, informed permission, and possible exploitation of genetic data provide major difficulties. distinct nations and areas have distinct regulatory systems controlling biobanking techniques, which generates compliance challenges for worldwide activities. Complicating the ethical and legal sides of biobanking include issues such sample ownership, benefit-sharing, and the right to withdraw consent. Furthermore, the long-term preservation of biological specimens begs issues about future usage and re-consent needs. These ethical and legal obstacles might hinder cross-border cooperation, complicate sample collecting, and raise biobank running expenses. Dealing with these issues calls for constant communication among interested parties, the creation of uniform ethical rules, and the application of strong governance systems to guarantee responsible biobanking methods and thereby support scientific progress.
Sample Type Segment dominated by blood products Still the most often gathered and used biospecimens in biobanking are blood products.
By sample type, the blood products segment—which includes whole blood, plasma, and serum—accounts for the most portion of the biobanking market. Ideal for large-scale biobanking activities, blood samples are rather simple to gather, handle, and store relative to other biospecimens. Studies in genomes, proteomics, and metabolomics as well as other fields of research depend much on these samples. Blood-based biospecimens are gathered and stored in response to the increased need for liquid biopsies in cancer research and diagnostics.
North America Leading Global Biobanking Market Strong research environment and advanced healthcare infrastructure propel regional supremacy.
Driven by well-established healthcare systems, major R&D investments, and a strong biotechnology sector, North America has the highest proportion of the worldwide biobanking market. Leading pharmaceutical businesses, research institutes, and government projects endorsing biomedical research help the area. Particularly the United States has a sizable network of biobanks and biorepositories including sizable population-based ones. Furthermore supporting the region's market leadership are good regulatory systems and growing attention on precision medicine. Further driving market expansion in North America are the increasing acceptance of cutting-edge biobanking technologies and the predominance of chronic diseases.
The mix of established firms and startups that defines the biobanking sector helps to create a competitive climate motivated by strategic alliances and technical innovation. Important players in the market concentrate on increasing their capacity for sample collecting, improving storage options, and creating combined biobanking management systems. Common ways to improve market position and increase service offers are mergers and acquisitions. Advanced data management systems are also under investment by businesses to enable research cooperation and offer complete sample data. Aiming to speed medication discovery and development processes, alliances between biobanks, pharmaceutical corporations, and research institutes help to further define the competitive scene. Market competitors are differentiating themselves with customized services including unique collecting procedures and biomarker validation support as the demand for premium biospecimens keeps increasing.
Thermo Fisher Scientific Inc.
Brooks Automation, Inc.
Hamilton Company
Merck KGaA
PHC Holdings Corporation
QIAGEN N.V.
Chart Industries, Inc.
Tecan Trading AG
VWR International, LLC
Becton, Dickinson and Company
Worthington Industries, Inc.
Biolife Solutions, Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Biobanking Market (2018 – 2022)
3.2. Global Biobanking Market (2023 – 2031)
3.2.1. Market Segment By Sample Type (2023 – 2031)
3.2.2. Market Segment By Application (2023 – 2031)
3.2.3. Market Segment By Storage Type (2023 – 2031)
3.2.4. Market Segment By End User (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Adoption of automation and robotics in biobanking operations to enhance efficiency and sample integrity
4.1.2. Integration of artificial intelligence in biospecimen management and analysis
4.1.3. Rise of virtual biobanks and cloud-based sample management systems
4.2. Market Drivers
4.2.1. Growing focus on precision medicine and biomarker discovery fuels demand for high-quality biospecimens
4.2.2. Increasing prevalence of chronic diseases and cancer driving biospecimen collection
4.2.3. Advancements in biopreservation technologies enhancing sample quality and longevity
4.3. Market Restraints
4.3.1. Ethical and regulatory challenges associated with biospecimen collection and utilization
4.3.2. High costs associated with biobanking infrastructure and maintenance
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY SAMPLE TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Blood Products
5.2. Human Tissues
5.3. Cell Lines
5.4. Nucleic Acids
6. BY APPLICATION
6.1. Regenerative Medicine
6.2. Life Science Research
6.3. Clinical Research
7. BY STORAGE TYPE
7.1. Manual Storage
7.2. Automated Storage
8. BY END USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Hospitals & Diagnostic Centers
8.3. Research Institutes
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. Thermo Fisher Scientific Inc.
12.2. Brooks Automation, Inc.
12.3. Hamilton Company
12.4. Merck KGaA
12.5. PHC Holdings Corporation
12.6. QIAGEN N.V.
12.7. Chart Industries, Inc.
12.8. Tecan Trading AG
12.9. VWR International, LLC
12.10. Becton, Dickinson and Company
12.11. Worthington Industries, Inc.
12.12. Biolife Solutions, Inc.
13. MARKET OPPORTUNITIES
By Sample Type:
Blood Products
Human Tissues
Cell Lines
Nucleic Acids
By Application:
Regenerative Medicine
Life Science Research
Clinical Research
By Storage Type:
Manual Storage
Automated Storage
By End User:
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Centers
Research Institutes
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
